BIOCOMPATIBLES INTERNAT. PLC was ist da los ?? - 500 Beiträge pro Seite
eröffnet am 08.03.02 20:35:35 von
neuester Beitrag 10.03.02 11:46:18 von
neuester Beitrag 10.03.02 11:46:18 von
Beiträge: 2
ID: 563.161
ID: 563.161
Aufrufe heute: 0
Gesamt: 210
Gesamt: 210
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| 01.04.24, 10:52 | 259 | |
| gestern 21:20 | 242 | |
| heute 01:24 | 220 | |
| 22.06.20, 20:50 | 172 | |
| gestern 19:37 | 140 | |
| heute 00:34 | 126 | |
| gestern 22:23 | 111 | |
| gestern 23:03 | 105 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.737,36 | -0,56 | 198 | |||
| 2. | 2. | 147,05 | -1,92 | 95 | |||
| 3. | 7. | 6,6320 | -1,43 | 70 | |||
| 4. | 5. | 0,1810 | -1,90 | 51 | |||
| 5. | Neu! | 713,65 | -23,14 | 46 | |||
| 6. | 8. | 3,7700 | +0,80 | 45 | |||
| 7. | 17. | 7,2900 | -0,21 | 43 | |||
| 8. | 4. | 2.390,60 | 0,00 | 41 |
Feedback
@Alle
Warum geht der Wert so stark in Richtung Süden ???
Wer hat Infos.
Mike29
Warum geht der Wert so stark in Richtung Süden ???
Wer hat Infos.
Mike29
Hi Mike,
hängt vielleicht damit zusammen
8 March 2002
This announcement is issued jointly by British Biotech and Biocompatibles International plc
Suspension of patient recruitment in the BRILLIANT II clinical trial for the Batimastat BiodivYsio® stent
Biocompatibles (LSE: BII) and British Biotech (LSE: BBG, NASDAQ: BBIOY) announced today that recruitment in BRILLIANT II, the double-blind pivotal clinical trial designed to secure CE Mark Approval for the Batismastat BiodivYsio® stent in Europe, has been suspended pending review of further data from the BRILLIANT I clinical trial. BRILLIANT I is a 150 patient multi-centre open clinical trial, recruitment for which was completed in November 2001. Six-month angiographic and clinical follow-up on an initial group of patients from BRILLIANT I has indicated that the Batimastat BiodivYsio® stent did not show the benefit that was evident in the pre-clinical studies.
A further announcement on the Batimastat BiodivYsio® stent programme, including the status of the IDE filing in the United States, will be made when further data from BRILLIANT I are available.
---ends---
hängt vielleicht damit zusammen
8 March 2002
This announcement is issued jointly by British Biotech and Biocompatibles International plc
Suspension of patient recruitment in the BRILLIANT II clinical trial for the Batimastat BiodivYsio® stent
Biocompatibles (LSE: BII) and British Biotech (LSE: BBG, NASDAQ: BBIOY) announced today that recruitment in BRILLIANT II, the double-blind pivotal clinical trial designed to secure CE Mark Approval for the Batismastat BiodivYsio® stent in Europe, has been suspended pending review of further data from the BRILLIANT I clinical trial. BRILLIANT I is a 150 patient multi-centre open clinical trial, recruitment for which was completed in November 2001. Six-month angiographic and clinical follow-up on an initial group of patients from BRILLIANT I has indicated that the Batimastat BiodivYsio® stent did not show the benefit that was evident in the pre-clinical studies.
A further announcement on the Batimastat BiodivYsio® stent programme, including the status of the IDE filing in the United States, will be made when further data from BRILLIANT I are available.
---ends---
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 196 | ||
| 93 | ||
| 66 | ||
| 50 | ||
| 46 | ||
| 43 | ||
| 42 | ||
| 37 | ||
| 33 | ||
| 27 |
| Wertpapier | Beiträge | |
|---|---|---|
| 23 | ||
| 21 | ||
| 20 | ||
| 20 | ||
| 20 | ||
| 19 | ||
| 18 | ||
| 18 | ||
| 15 | ||
| 15 |
